asthma
AstraZeneca’s Trixeo gets EU approval for asthma maintenance treatment
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
AstraZeneca’s Baxfendy approved by US FDA for adults with uncontrolled hypertension
Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment
Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need
AstraZeneca shares late-stage results for Airsupra in mild asthma patients
More than ten million asthma exacerbations occur in the US every year
AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma
Up to 262 million people worldwide are affected by the chronic respiratory disease
Chiesi report highlights incorrect inhaler use among UK asthma patients
The long-term lung condition affects around 7.2 million people in the UK
Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn
Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients
UK researchers uncover first new asthma and COPD attack treatment in 50 years
The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings
AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra
The chronic respiratory disease is estimated to affect up to 262 million people globally